Skip to main content

Advertisement

SpringerLink
Log in

Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer.

Patients and methods

Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 100 mg/m2 plus cisplatin 35 mg/m2 on days 1 and 8 based on a 3-week cycle.

Results

Fifty-two patients were enrolled in the current study. Two complete responses and 17 partial responses were confirmed, giving an overall response rate of 36.5%. At a median follow-up of 8.5 months, the median time to progression and median overall survival was 6.0 and 10.8 months, respectively. Grade 3 neutropenia occurred in ten patients, while no grade 4 neutropenia or febrile neutropenia was observed. The most common non-hematologic toxicity was nausea (grade 1/2, 56.9%). There were no treatment-related deaths.

Conclusion

A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29

    Article  PubMed  CAS  Google Scholar 

  2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Ransch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41

    Article  PubMed  CAS  Google Scholar 

  3. Pyrhonen S, Kuitunen T, Kouri M (1995) A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Br J Cancer 71:587–591

    PubMed  CAS  Google Scholar 

  4. Glimelius B, Hoffmann K, Haglund U, Nyron O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive in advanced gastric cancer. Ann Oncol 5:189–190

    PubMed  CAS  Google Scholar 

  5. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3818

    Article  PubMed  CAS  Google Scholar 

  6. Vanhoefer U, Wagner T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, Baron B, Wilke H, Wils J (2001) Randomized phase II study of weekly 24-h infusion of high dose 5-FU ± folinic acid (HD-FU ± FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Eur J Cancer 37:27

    Article  Google Scholar 

  7. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Hermann R, Honegger H, Cavalli F, Alberto P, Castighine M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol 11:301–306

    Article  PubMed  CAS  Google Scholar 

  8. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323

    PubMed  CAS  Google Scholar 

  9. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667

    Article  PubMed  CAS  Google Scholar 

  10. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816–825

    PubMed  CAS  Google Scholar 

  11. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  12. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF (1998) Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4:269–274

    PubMed  CAS  Google Scholar 

  13. Bokemeyer C, Lampe CS, Clemens MR, Hartmann JT, Quietzsch D, Forkmann L, Kollmannsberger C, Kanz L (1997) A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8:396–399

    Article  PubMed  CAS  Google Scholar 

  14. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempd V, Uemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458–462

    Article  PubMed  CAS  Google Scholar 

  15. Kim MK, Lee KH, Hyun MS, Do YR, Song HS, Lee WS, Park KU, Baek JH, Kim JG (2005) A multi-center, phase II clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat 37:349–353

    Article  Google Scholar 

  16. Georgiadis MS, Russell EK, Gazdar AF, Johnson BE (1997) Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin Cancer Res 3:449–454

    PubMed  CAS  Google Scholar 

  17. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104–1109

    PubMed  CAS  Google Scholar 

  18. Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T (1997) Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother Pharmacol 40:245–250

    Article  PubMed  CAS  Google Scholar 

  19. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480–2486

    Article  PubMed  CAS  Google Scholar 

  20. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353–3361

    PubMed  CAS  Google Scholar 

  21. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365–2369

    Article  PubMed  CAS  Google Scholar 

  22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan JS, Rubinstein L, Verweij J, Van Glabbeke M, Van Qosterom At, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10

    Article  PubMed  CAS  Google Scholar 

  24. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK (2004) A multi-center, late phase II clinical trial of genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 12:1059–1064

    PubMed  CAS  Google Scholar 

  25. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS (1999) Paclitaxel, 5-flourouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85:295–301

    Article  PubMed  CAS  Google Scholar 

  26. Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C (2002) Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13:497–503

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by a grant of the Korean Health 21 R&D Project, Ministry of Heath & Welfare, Republic of Korea (0412-CR01-0704-0001).

Author information

Authors and Affiliations

  1. Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea

    Jong Gwang Kim & Sang Kyun Sohn

  2. Department of Oncology/Hematology, Dongsan Medical Center, Keimyung University School of Medicine, 194 Dongsan-dong, Jung-ku, Daegu, 700-712, Korea

    Hong Suk Song, Ki-Young Kwon & Young Rok Do

  3. Department of Oncology/Hematology, Yeungnam University Hospital, Daegu, Korea

    Kyung Hee Lee & Myung Soo Hyun

  4. Department of Oncology/Hematology, Daegu Catholic University Medical Center, Daegu Catholic University School of Medicine, Daegu, Korea

    Hun Mo Ryoo & Sung Hwa Bae

  5. Department of Oncology/Hematology, Dongguk University Medical Center, Dongguk University College of Medicine, Gyeongju, Korea

    Keon Uk Park & Jin Ho Baek

  6. Department of Oncology/Hematology, Daegu Fatima Hospital, Daegu, Korea

    Won Sik Lee

  7. Department of Oncology/Hematology, Pusan National University Hospital, Busan, Korea

    Joo Seop Chung & Goon Jae Cho

  8. Department of Oncology/Hematology, Inje University Hospital, Busan, Korea

    Chang-Hak Sohn

  9. Department of Oncology/Hematology, Gyeongsang National University Hospital, Jinju, Korea

    Jung Soon Jang

  10. Department of General Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea

    Ho Young Chung & Wansik Yu

Authors
  1. Jong Gwang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang Kyun Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong Suk Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ki-Young Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Young Rok Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kyung Hee Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Myung Soo Hyun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hun Mo Ryoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sung Hwa Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keon Uk Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jin Ho Baek
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Won Sik Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Joo Seop Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Goon Jae Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Chang-Hak Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jung Soon Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ho Young Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Wansik Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Suk Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.G., Sohn, S.K., Song, H.S. et al. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 60, 863–869 (2007). https://doi.org/10.1007/s00280-007-0433-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0433-8

Keywords

Search

Navigation